Base de dados : MEDLINE
Pesquisa : G12.875 [Categoria DeCS]
Referências encontradas : 14167 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1417 ir para página                         

  1 / 14167 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29335408
[Au] Autor:Ju JM; Jung MH; Nam G; Kim W; Oh S; Kim HD; Kim JY; Chang J; Lee SH; Park GS; Min CK; Lee DS; Kim MG; Choi K; Choi EY
[Ad] Endereço:Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, 03080, Korea.
[Ti] Título:Escape from thymic deletion and anti-leukemic effects of T cells specific for hematopoietic cell-restricted antigen.
[So] Source:Nat Commun;9(1):225, 2018 01 15.
[Is] ISSN:2041-1723
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Whether hematopoietic cell-restricted distribution of antigens affects the degree of thymic negative selection has not been investigated in detail. Here, we show that T cells specific for hematopoietic cell-restricted antigens (HRA) are not completely deleted in the thymus, using the mouse minor histocompatibility antigen H60, the expression of which is restricted to hematopoietic cells. As a result, low avidity T cells escape from thymic deletion. This incomplete thymic deletion occurs to the T cells developing de novo in the thymus of H60-positive recipients in H60-mismatched bone marrow transplantation (BMT). H60-specific thymic deletion escapee CD8 T cells exhibit effector differentiation potentials in the periphery and contribute to graft-versus-leukemia effects in the recipients of H60-mismatched BMT, regressing H60 hematological tumors. These results provide information essential for understanding thymic negative selection and developing a strategy to treat hematological tumors.
[Mh] Termos MeSH primário: Linfócitos T CD8-Positivos/imunologia
Células-Tronco Hematopoéticas/imunologia
Antígenos de Histocompatibilidade Menor/imunologia
Timo/imunologia
[Mh] Termos MeSH secundário: Animais
Células Apresentadoras de Antígenos/imunologia
Células Apresentadoras de Antígenos/metabolismo
Transplante de Medula Óssea/métodos
Linfócitos T CD8-Positivos/metabolismo
Citometria de Fluxo
Células-Tronco Hematopoéticas/metabolismo
Camundongos Knockout
Camundongos Transgênicos
Antígenos de Histocompatibilidade Menor/genética
Antígenos de Histocompatibilidade Menor/metabolismo
Timócitos/imunologia
Timócitos/metabolismo
Timo/metabolismo
Imunologia de Transplantes/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Minor Histocompatibility Antigens); 0 (minor H antigen H60)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180117
[St] Status:MEDLINE
[do] DOI:10.1038/s41467-017-02665-z


  2 / 14167 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27773449
[Au] Autor:Cajita MI; Denhaerynck K; Dobbels F; Berben L; Russell CL; Davidson PM; De Geest S; BRIGHT study team
[Ad] Endereço:School of Nursing, Johns Hopkins University, Baltimore, Maryland, USA.
[Ti] Título:Health literacy in heart transplantation: Prevalence, correlates and associations with health behaviors-Findings from the international BRIGHT study.
[So] Source:J Heart Lung Transplant;36(3):272-279, 2017 03.
[Is] ISSN:1557-3117
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Health literacy (HL) is a major determinant of health outcomes; however, there are few studies exploring the role of HL among heart transplant recipients. The objectives of this study were to: (1) explore and compare the prevalence of inadequate HL among heart transplant recipients internationally; (2) determine the correlates of HL; and (3) assess the relationship between HL and health-related behaviors. METHODS: A secondary analysis was conducted using data of the 1,365 adult patients from the BRIGHT study, an international multicenter, cross-sectional study that surveyed heart transplant recipients across 11 countries and 4 continents. Using the Subjective Health Literacy Screener, inadequate HL was operationalized as being confident in filling out medical forms none/a little/some of the time (HL score of 0 to 2). Correlates of HL were determined using backward stepwise logistic regression. The relationship between HL and the health-related behaviors were examined using hierarchical logistic regression. RESULTS: Overall, 33.1% of the heart transplant recipients had inadequate HL. Lower education level (adjusted odds ratio [AOR] 0.24, p < 0.001), unemployment (AOR 0.69, p = 0.012) and country (residing in Brazil, AOR 0.25, p < 0.001) were shown to be associated with inadequate HL. Heart transplant recipients with adequate HL had higher odds of engaging in sufficient physical activity (AOR 1.6, p = 0.016). HL was not significantly associated with the other health behaviors. CONCLUSIONS: Clinicians should recognize that almost one third of heart transplant participants have inadequate health literacy. Furthermore, they should adopt communication strategies that could mitigate the potential negative impact of inadequate HL.
[Mh] Termos MeSH primário: Rejeição de Enxerto/etiologia
Comportamentos Relacionados com a Saúde
Alfabetização em Saúde
Transplante de Coração/métodos
Imunossupressores/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Fatores Etários
Idoso
Intervalos de Confiança
Estudos Transversais
Feminino
Rejeição de Enxerto/mortalidade
Rejeição de Enxerto/fisiopatologia
Transplante de Coração/efeitos adversos
Transplante de Coração/mortalidade
Seres Humanos
Internacionalidade
Estilo de Vida
Modelos Logísticos
Masculino
Meia-Idade
Determinação de Necessidades de Cuidados de Saúde
Cooperação do Paciente
Prevalência
Prognóstico
Fatores Sexuais
Taxa de Sobrevida
Imunologia de Transplantes
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Immunosuppressive Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  3 / 14167 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29385359
[Au] Autor:Sarantopoulos S
[Ad] Endereço:From the Department of Medicine, Division of Hematological Malignancies and Cellular Therapy, Duke Cancer Institute, Duke University Medical Center, Durham, NC.
[Ti] Título:Allogeneic Stem-Cell Transplantation - A T-Cell Balancing ACT.
[So] Source:N Engl J Med;378(5):480-482, 2018 Feb 01.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Transplante de Células-Tronco Hematopoéticas
Interleucina-33/metabolismo
Subpopulações de Linfócitos T/imunologia
Imunologia de Transplantes
[Mh] Termos MeSH secundário: Transferência Adotiva
Animais
Antígenos CD
Modelos Animais de Doenças
Interleucina-9/biossíntese
Camundongos
Transplante Homólogo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, CD); 0 (Interleukin-33); 0 (Interleukin-9)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMcibr1713238


  4 / 14167 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29368839
[Au] Autor:Shilov ES; Kuprash DV
[Ti] Título:[Genetic mechanisms of adaptive immunity emergence in vertebrates].
[So] Source:Genetika;52(7):761-73, 2016 Jul.
[Is] ISSN:0016-6758
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The adaptive immune system in vertebrates emerged in a multistep process that can be reconstructed on the basis of the data concerning the structure of immune systems of modern cartilaginous and bony fishes, as well as of cyclostomes. The most probable evolutionary scenario is likely to be as follows: the T cell receptor loci emerged on the basis of NK cell-like receptor genes; the antibody loci evolved on the basis of T cell receptor loci; the MHC locus arose on the basis of the locus responsible for innate immunity of early chordates. The ancestral MHC molecules likely participated in the transplantation immunity before they acquired the ability of antigen peptide presentation.
[Mh] Termos MeSH primário: Imunidade Adaptativa/genética
Anticorpos/genética
Apresentação do Antígeno/genética
Complexo Principal de Histocompatibilidade
Receptores de Antígenos de Linfócitos T/genética
Imunologia de Transplantes/genética
[Mh] Termos MeSH secundário: Animais
Anticorpos/imunologia
Loci Gênicos/imunologia
Seres Humanos
Receptores de Antígenos de Linfócitos T/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies); 0 (Receptors, Antigen, T-Cell)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE


  5 / 14167 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27771741
[Au] Autor:Owonikoko TK; Kumar M; Yang S; Kamphorst AO; Pillai RN; Akondy R; Nautiyal V; Chatwal MS; Book WM; Sahu A; Sica GL; Ahmed R; Ramalingam SS
[Ad] Endereço:Department of Hematology and Medical Oncology, Emory University School of Medicine, 1365-C Clifton Road, NE, Suite C3080, Atlanta, GA, 30322, USA. towonik@emory.edu.
[Ti] Título:Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report.
[So] Source:Cancer Immunol Immunother;66(1):45-50, 2017 Jan.
[Is] ISSN:1432-0851
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The increased availability of immunotherapeutic agents for the treatment of a wide array of cancer in the general oncology practice setting will reveal rare and unique toxicities. MATERIALS AND METHODS: The mechanism of cardiac allograft rejection in the context of PD-1 antibody therapy was explored in a patient with cutaneous squamous cell cancer complicating long-standing cardiac allograft. Immune cell infiltrate in the myocardium and peripheral blood lymphocyte repertoire were assessed using myocardial biopsy and temporal analysis of peripheral blood samples. The efficacy of high-intensity immunosuppression to reverse graft rejection was explored. RESULTS: Endomyocardial biopsy showed acute moderate diffuse cellular rejection with a predominant population of CD3+, CD8+ and CD4+ infiltrating lymphocytes; peripheral blood circulating lymphocytes showed a high frequency of proliferating and activated CD8+ T cells expressing PD-1 compared to a normal control. There was no difference in the activation and proliferation of CD4+ T cells compared to a normal control. Cardiac function improved following high-intensity immunosuppression and patient survived for up to 7 months after discontinuation of nivolumab. CONCLUSIONS: Immune checkpoint inhibitors should be avoided in allograft recipients but high-intensity immunosuppression is effective to salvage allograft rejection induced by these agents.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/efeitos adversos
Carcinoma de Células Escamosas/tratamento farmacológico
Rejeição de Enxerto/induzido quimicamente
Transplante de Coração/efeitos adversos
Neoplasias/imunologia
Receptor de Morte Celular Programada 1/antagonistas & inibidores
Neoplasias Cutâneas/tratamento farmacológico
[Mh] Termos MeSH secundário: Aloenxertos
Anticorpos Monoclonais/administração & dosagem
Carcinoma de Células Escamosas/imunologia
Rejeição de Enxerto/imunologia
Transplante de Coração/métodos
Seres Humanos
Imunoterapia/efeitos adversos
Imunoterapia/métodos
Masculino
Meia-Idade
Receptor de Morte Celular Programada 1/imunologia
Neoplasias Cutâneas/imunologia
Imunologia de Transplantes
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (PDCD1 protein, human); 0 (Programmed Cell Death 1 Receptor); 31YO63LBSN (nivolumab)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180101
[Lr] Data última revisão:
180101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1007/s00262-016-1918-2


  6 / 14167 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28798075
[Au] Autor:Striz I
[Ad] Endereço:Department of Clinical and Transplant Immunology, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 14021 Prague 4, Czech Republic ilja.striz@ikem.cz.
[Ti] Título:Cytokines of the IL-1 family: recognized targets in chronic inflammation underrated in organ transplantations.
[So] Source:Clin Sci (Lond);131(17):2241-2256, 2017 Sep 01.
[Is] ISSN:1470-8736
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Interleukin 1 (IL-1) family is a group of cytokines with multiple local and systemic effects, which regulates both innate and adaptive immune responses. Generally, most IL-1 family cytokines express prevailing pro-inflammatory activities (IL-1α, IL-1ß, IL-18, IL-33, IL-36 α, ß, γ), whereas others are anti-inflammatory (IL-1Ra (IL-1 receptor antagonist), IL-36Ra, IL-38, IL-37). In addition to their immunomodulatory roles, some of them are also involved in the physiological modulation of homeostatic processes and directly affect mRNA transcription. IL-1 family cytokines bind to specific receptors composed of a ligand-binding chain and an accessory chain. The pro-inflammatory effects of IL-1 family cytokines are regulated on the level of transcription, enzymatic processing of precursors, release of soluble antagonists, and expression of decoy receptors. Members of the IL-1 family regulate the recruitment and activation of effector cells involved in innate and adaptive immunity, but they are also involved in the pathogenesis of chronic disorders, including inflammatory bowel disease, rheumatoid arthritis, and various autoimmune and autoinflammatory diseases. There are only limited data regarding the role of IL-1 cytokines in transplantation. In recent years, targeted therapeutics affecting IL-1 have been used in multiple clinical studies. In addition to the recombinant IL-1Ra, anakinra (highly effective in autoinflammatory diseases and tested for other chronic diseases), the monoclonal antibodies canakinumab, gevokizumab, and rilonacept (a long-acting IL-1 receptor fusion protein) provide further options to block IL-1 activity. Furthermore, new inhibitors of IL-18 (GSK 1070806, ABT-325, rIL-18BP (IL-18 binding protein)) and IL-33 (CNTO-7160) are presently under clinical studies and other molecules are being developed to target IL-1 family cytokines.
[Mh] Termos MeSH primário: Inflamação/imunologia
Interleucina-1/imunologia
Família Multigênica
Imunologia de Transplantes
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Inflamação/genética
Interleucina-1/genética
Transplante de Órgãos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Interleukin-1)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170913
[Lr] Data última revisão:
170913
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170812
[St] Status:MEDLINE
[do] DOI:10.1042/CS20170098


  7 / 14167 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28784214
[Au] Autor:Holt CD
[Ad] Endereço:Clinical Research Program, UCLA Department of Surgery, Dumont-UCLA Transplant Center, David Geffen School of Medicine at UCLA, 650 CE Young Drive South, Room 77-123CHS, Los Angeles, CA 90095-7054, USA. Electronic address: cholt@mednet.ucla.edu.
[Ti] Título:Overview of Immunosuppressive Therapy in Solid Organ Transplantation.
[So] Source:Anesthesiol Clin;35(3):365-380, 2017 Sep.
[Is] ISSN:1932-2275
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Mechanisms of rejection, new pharmacologic approaches, and genomic medicine are major foci for current research in transplantation. It is hoped that these new agents and personalized immunosuppression will provide for less toxic regimens that are effective in preventing both acute and chronic allograft rejection. Until new agents are available, practitioners must use various combinations of currently approved agents to find the best regimens for improved long-term outcomes.
[Mh] Termos MeSH primário: Imunossupressores/farmacologia
Transplante de Órgãos
[Mh] Termos MeSH secundário: Seres Humanos
Imunossupressão
Imunossupressores/farmacocinética
Imunossupressores/uso terapêutico
Imunologia de Transplantes
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Immunosuppressive Agents)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170809
[St] Status:MEDLINE


  8 / 14167 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
Texto completo
[PMID]:28767349
[Au] Autor:Jordan SC; Lorant T; Choi J; Kjellman C; Winstedt L; Bengtsson M; Zhang X; Eich T; Toyoda M; Eriksson BM; Ge S; Peng A; Järnum S; Wood KJ; Lundgren T; Wennberg L; Bäckman L; Larsson E; Villicana R; Kahwaji J; Louie S; Kang A; Haas M; Nast C; Vo A; Tufveson G
[Ad] Endereço:From the Comprehensive Transplant Center (S.C.J., J.C., M.T., S.G., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunotherapy Program (S.C.J., J.C., A.P., R.V., J.K., S.L., A.K., A.V.), Transplant Immunology Laboratory (S.C.J., M.T., S.G.), HLA Laboratory (X.Z.), and the Department of Pathology
[Ti] Título:IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation.
[So] Source:N Engl J Med;377(5):442-453, 2017 08 03.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Donor-specific antibodies create an immunologic barrier to transplantation. Current therapies to modify donor-specific antibodies are limited and ineffective in the most highly HLA-sensitized patients. The IgG-degrading enzyme derived from Streptococcus pyogenes (IdeS), an endopeptidase, cleaves human IgG into F(ab') and Fc fragments inhibiting complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, which suggests that IdeS might be useful for desensitization. We report on the combined experience of two independently performed open-label, phase 1-2 trials (conducted in Sweden and the United States) that assessed the efficacy of IdeS with regard to desensitization and transplantation of a kidney from an HLA-incompatible donor. METHODS: We administered IdeS to 25 highly HLA-sensitized patients (11 patients in Uppsala or Stockholm, Sweden, and 14 in Los Angeles) before the transplantation of a kidney from an HLA-incompatible donor. Frequent monitoring for adverse events, outcomes, donor-specific antibodies, and renal function was performed, as were renal biopsies. Immunosuppression after transplantation consisted of tacrolimus, mycophenolate mofetil, and glucocorticoids. Patients in the U.S. study also received intravenous immune globulin and rituximab after transplantation to prevent antibody rebound. RESULTS: Recipients in the U.S. study had a significantly longer cold ischemia time (the time elapsed between procurement of the organ and transplantation), a significantly higher rate of delayed graft function, and significantly higher levels of class I donor-specific antibodies than those in the Swedish study. A total of 38 serious adverse events occurred in 15 patients (5 events were adjudicated as being possibly related to IdeS). At transplantation, total IgG and HLA antibodies were eliminated. A total of 24 of 25 patients had perfusion of allografts after transplantation. Antibody-mediated rejection occurred in 10 patients (7 patients in the U.S. study and 3 in the Swedish study) at 2 weeks to 5 months after transplantation; all these patients had a response to treatment. One graft loss, mediated by non-HLA IgM and IgA antibodies, occurred. CONCLUSIONS: IdeS reduced or eliminated donor-specific antibodies and permitted HLA-incompatible transplantation in 24 of 25 patients. (Funded by Hansa Medical; ClinicalTrials.gov numbers, NCT02224820 , NCT02426684 , and NCT02475551 .).
[Mh] Termos MeSH primário: Proteínas de Bactérias/uso terapêutico
Cisteína Endopeptidases/uso terapêutico
Antígenos HLA/imunologia
Imunossupressão/métodos
Transplante de Rim
Imunologia de Transplantes
[Mh] Termos MeSH secundário: Adulto
Anticorpos/sangue
Proteínas de Bactérias/efeitos adversos
Complemento C1q/imunologia
Cisteína Endopeptidases/efeitos adversos
Feminino
Teste de Histocompatibilidade
Seres Humanos
Imunoglobulina G/sangue
Imunoglobulina G/metabolismo
Masculino
Meia-Idade
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Antibodies); 0 (Bacterial Proteins); 0 (HLA Antigens); 0 (Immunoglobulin G); 0 (Mac-1-like protein, Streptococcus); 80295-33-6 (Complement C1q); EC 3.4.22.- (Cysteine Endopeptidases)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170803
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMoa1612567


  9 / 14167 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28729289
[Au] Autor:Wiebe C; Rush DN; Nevins TE; Birk PE; Blydt-Hansen T; Gibson IW; Goldberg A; Ho J; Karpinski M; Pochinco D; Sharma A; Storsley L; Matas AJ; Nickerson PW
[Ad] Endereço:Departments of Medicine, cwiebe@hsc.mb.ca.
[Ti] Título:Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development.
[So] Source:J Am Soc Nephrol;28(11):3353-3362, 2017 Nov.
[Is] ISSN:1533-3450
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Despite more than two decades of use, the optimal maintenance dose of tacrolimus for kidney transplant recipients is unknown. We hypothesized that HLA class II donor-specific antibody ( DSA) development correlates with tacrolimus trough levels and the recipient's individualized alloimmune risk determined by HLA-DR/DQ epitope mismatch. A cohort of 596 renal transplant recipients with 50,011 serial tacrolimus trough levels had HLA-DR/DQ eplet mismatch determined using HLAMatchmaker software. We analyzed the frequency of tacrolimus trough levels below a series of thresholds <6 ng/ml and the mean tacrolimus levels before DSA development in the context of HLA-DR/DQ eplet mismatch. HLA-DR/DQ eplet mismatch was a significant multivariate predictor of DSA development. Recipients treated with a cyclosporin regimen had a 2.7-fold higher incidence of DSA development than recipients on a tacrolimus regimen. Recipients treated with tacrolimus who developed HLA-DR/DQ DSA had a higher proportion of tacrolimus trough levels <5 ng/ml, which continued to be significant after adjustment for HLA-DR/DQ eplet mismatch. Mean tacrolimus trough levels in the 6 months before DSA development were significantly lower than the levels >6 months before DSA development in the same patients. Recipients with a high-risk HLA eplet mismatch score were less likely to tolerate low tacrolimus levels without developing DSA. We conclude that HLA-DR/DQ eplet mismatch and tacrolimus trough levels are independent predictors of DSA development. Recipients with high HLA alloimmune risk should not target tacrolimus levels <5 ng/ml unless essential, and monitoring for DSA may be advisable in this setting.
[Mh] Termos MeSH primário: Rejeição de Enxerto/imunologia
Rejeição de Enxerto/prevenção & controle
Antígenos HLA-D/imunologia
Imunossupressores/administração & dosagem
Imunossupressores/sangue
Transplante de Rim
Tacrolimo/administração & dosagem
Tacrolimo/sangue
[Mh] Termos MeSH secundário: Adulto
Rejeição de Enxerto/sangue
Seres Humanos
Imunologia de Transplantes
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (HLA-D Antigens); 0 (Immunosuppressive Agents); WM0HAQ4WNM (Tacrolimus)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170722
[St] Status:MEDLINE
[do] DOI:10.1681/ASN.2017030287


  10 / 14167 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28530643
[Au] Autor:Todd JL; Palmer SM
[Ad] Endereço:Duke University Medical Center, Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Durham, North Carolina, USA.
[Ti] Título:Danger signals in regulating the immune response to solid organ transplantation.
[So] Source:J Clin Invest;127(7):2464-2472, 2017 Jun 30.
[Is] ISSN:1558-8238
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Endogenous danger signals, or damage-associated molecular patterns (DAMPs), are generated in response to cell stress and activate innate immunity to provide a pivotal mechanism by which an organism can respond to damaged self. Accumulating experimental and clinical data have established the importance of DAMPs, which signal through innate pattern recognition receptors (PRRs) or DAMP-specific receptors, in regulating the alloresponse to solid organ transplantation (SOT). Moreover, DAMPs may incite distinct downstream cellular responses that could specifically contribute to the development of allograft fibrosis and chronic graft dysfunction. A growing understanding of the role of DAMPs in directing the immune response to transplantation has suggested novel avenues for the treatment or prevention of allograft rejection that complement contemporary immunosuppression and could lead to improved outcomes for solid organ recipients.
[Mh] Termos MeSH primário: Imunidade Inata
Transplante de Órgãos
Transdução de Sinais/imunologia
Imunologia de Transplantes
[Mh] Termos MeSH secundário: Animais
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170523
[St] Status:MEDLINE



página 1 de 1417 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde